For research use only. Not for therapeutic Use.
Mitoguazone（Cat No.:I007998）is a potent polyamine synthesis inhibitor that targets the enzyme S-adenosylmethionine decarboxylase (SAMDC), disrupting polyamine biosynthesis critical for cell proliferation. This mechanism makes it a valuable tool in cancer research, particularly for studying tumor growth and metabolic pathways. Mitoguazone has shown potential in preclinical and clinical studies for treating various malignancies, including lymphomas and leukemias. Its role extends to exploring combination therapies and resistance mechanisms, supporting advancements in oncology and the development of targeted cancer treatments aimed at improving therapeutic outcomes.
| Catalog Number | I007998 |
| CAS Number | 459-86-9 |
| Synonyms | Mitoguazone; MeGAG; methylG; methylGAG; MGBG; MGGH; DRG0223; NSC32946.;(2E,2/’E)-2,2/’-(propane-1,2-diylidene)bis(hydrazinecarboximidamide) |
| Molecular Formula | C5H12N8 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at -20°C |
| IUPAC Name | 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine |
| InChI | InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+ |
| InChIKey | MXWHMTNPTTVWDM-NXOFHUPFSA-N |
| SMILES | C/C(=N\N=C(N)N)/C=N/N=C(N)N |
| Reference | </br>1:Administration of the antitumor drug mitoguazone protects normal thymocytes against spontaneous and etoposide-induced apoptosis. Ferioli ME, Bottone MG, Soldani C, Pellicciari C.Cell Mol Life Sci. 2004 Nov;61(21):2767-73. PMID: 15549180 </br>2:Effect of mitoguazone on polyamine oxidase activity in rat liver. Ferioli ME, Berselli D, Caimi S.Toxicol Appl Pharmacol. 2004 Dec 1;201(2):105-11. PMID: 15541750 </br>3:Treatment of AIDS related non-Hodgkin/’s lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM.Invest New Drugs. 2004 Jan;22(1):63-8. PMID: 14707495 </br>4:A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients. Ishmael DR, Chen WR, Hamilton SA, Liu H, Nordquist RE.Cancer Invest. 2003;21(4):542-9. PMID: 14533444 </br>5:Rapid and sensitive quantitation of the antiproliferative agent mitoguazone in small volumes of plasma by high-performance liquid chromatography with ultraviolet detection. Cheng CL, Lin EG, Chou CH.J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):281-9. PMID: 12906902 </br>6:Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors. Ishmael DR, Chen WR, Nordquist JA, Liu H, Nordquist RE.Cancer Invest. 2003 Apr;21(2):217-26. PMID: 12743987 </br>7:Polyamine oxidase activity in rats treated with mitoguazone: specific and permanent decrease in thymus. Ferioli ME, Armanni A.Amino Acids. 2003;24(1-2):187-94. PMID: 12624752 </br>8:Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G.Eur J Haematol Suppl. 2001 Jul;64:14-20. PMID: 11486395 </br>9:Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group. Wiernik PH, Gordon LI, Oken MM, Harris JE, O/’Connell MJ.Leuk Lymphoma. 1999 Oct;35(3-4):375-7. PMID: 10706462 </br>10:Mitoguazone induces apoptosis via a p53-independent mechanism. Davidson K, Petit T, Izbicka E, Koester S, Von Hoff DD.Anticancer Drugs. 1998 Aug;9(7):635-40. PMID: 9773808 |
